vTv Therapeutics Announces FDA Has Placed A Clinical Hold On The Cadisegliatin Clinical Program Which Includes The Ongoing CATT1 Phase 3 Trial In Type 1 Diabetes
Portfolio Pulse from Benzinga Newsdesk
vTv Therapeutics Inc. (NASDAQ:VTVT) announced that the FDA has placed a clinical hold on its cadisegliatin clinical program, including the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is a glucokinase activator that has been well-tolerated in over 500 subjects.
July 26, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA has placed a clinical hold on vTv Therapeutics' cadisegliatin clinical program, including the ongoing CATT1 Phase 3 trial in type 1 diabetes. This could delay the development and potential approval of cadisegliatin.
The FDA's clinical hold on the cadisegliatin program is a significant regulatory setback for vTv Therapeutics. This could delay the development timeline and potential market approval of cadisegliatin, negatively impacting investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100